Evropská unie - čeština - EMA (European Medicines Agency)

janssen-cilag international n.v.    - ponesimod - roztroušená skleróza, relaps-remitentní - imunosupresiva - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Evropská unie - čeština - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - roztroušená skleróza, relaps-remitentní - imunosupresiva - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).

Evropská unie - čeština - EMA (European Medicines Agency)

mylan ireland limited - dimethyl fumarát - roztroušená skleróza, relaps-remitentní - imunosupresiva - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Evropská unie - čeština - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimethyl fumarát - roztroušená skleróza, relaps-remitentní - imunosupresiva - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Evropská unie - čeština - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimethyl fumarát - roztroušená skleróza, relaps-remitentní - imunosupresiva - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Evropská unie - čeština - EMA (European Medicines Agency)

mylan pharmaceuticals limited - teriflunomid - roztroušená skleróza, relaps-remitentní - imunosupresiva - teriflunomide mylan is indicated for the treatment of adult patients and paediatric patients aged 10 years and older (body weight > 40 kg) with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 of the smpc for important information on the population for which efficacy has been established).

Evropská unie - čeština - EMA (European Medicines Agency)

accord healthcare s.l.u. - teriflunomid - roztroušená skleróza, relaps-remitentní - imunosupresiva, selektivní imunosupresiva - teriflunomide accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Evropská unie - čeština - EMA (European Medicines Agency)

sanofi-aventis groupe - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antitrombotické činidla - akutní koronární syndromemyocardial myokardu.

Evropská unie - čeština - EMA (European Medicines Agency)

covis pharma europe b.v. - formoterol fumarate dihydrate, aclidinium bromide - plicní onemocnění, chronická obstrukční - léky na obstrukční onemocnění dýchacích cest, - brimica genuair je indikován jako udržovací bronchodilatační léčba obstrukce proudění vzduchu a úlevu od příznaků u dospělých pacientů s chronickou obstrukční plicní nemocí (chopn).

Evropská unie - čeština - EMA (European Medicines Agency)

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infekce dýchacích syncyciálních virů - vakcíny - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. viz kapitoly 4. 2 a 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. použití této vakcíny musí být v souladu s oficiálními doporučeními.